scholarly journals 112: COVID-19-ASSOCIATED MYOCARDITIS TREATED WITH ECPELLA AND GLUCOCORTICOID THERAPY: A CASE SERIES

2021 ◽  
Vol 50 (1) ◽  
pp. 39-39
Author(s):  
Justin Kim ◽  
Sangrag Ganguli ◽  
David Yamane ◽  
Elizabeth Pocock ◽  
Ramesh Mazhari ◽  
...  
Keyword(s):  
Case Series ◽  
Glucocorticoid Therapy

scholarly journals Clinical observations of acute onset of myopic optic neuropathy in a real-world setting

2021 ◽  
Vol 14 (3) ◽  
pp. 461-467
Author(s):  
Li Liao ◽  
◽  
Fang Fang ◽  
Xiao-Hua Zhu ◽  
◽  
...  
Keyword(s):  
Clinical Features ◽  
Optic Neuropathy ◽  
Real World ◽  
Vision Loss ◽  
Case Series ◽  
Acute Onset ◽  
Glucocorticoid Therapy ◽  
Glucocorticoid Treatment ◽  
Real World Setting ◽  
Systemic Glucocorticoid

AIM: To describe the clinical features of acute myopic onset of optic neuropathy and observe the effects of retrobulbar and systemic glucocorticoid therapy in a real-world setting. METHODS: A retrospective observational case series included 18 patients with a clinical diagnosis of acute onset of myopic optic neuropathy in a real-world setting. While the patients were using retrobulbar and systemic glucocorticoid therapy, various imaging examination data were analysed, and the clinical features of myopic optic neuropathy were summarized for 6mo to 2y. RESULTS: The included group of patients with acute onset of myopic optic neuropathy consisted mostly of females (n=11). The visual field (VF) showed abnormalities in bilateral eyes, including the spread of physiological blind spots, central and paracentral dark spots, and centripetal peripheral VF reduction; but central vision with no subjective changes. The visual evoked potential (VEP) was abnormal in all eyes with vision loss. The best corrected visual acuity (BCVA) was improved from 1.04±0.63 to 0.47±0.57 (logMAR) after glucocorticoid treatment (P<0.05). In patients with a short course (within 1wk), recovery was fast and achieved the same BCVA as recorded before the onset within 6d. However, in patients with the long course (1 to 2wk), recovery was slow and did not achieve the BCVA recorded before the onset within 10d. The changes of intraocular pressure (IOP) were not obvious before and after treatment (18.68±5.30 vs 19.55±5.34 mm Hg, P>0.05). There was no recurrence during long-term follow-up observation. CONCLUSION: The acute onset of myopic optic neuropathy is characterized by BCVA and VF abnormalities in bilateral eyes. Retrobulbar and systemic glucocorticoid therapy is effective.

scholarly journals Diabetes Mellitus and Glucocorticoid Use As Risk Factors for COVID-19 Associated Mucormycosis

2021 ◽  
pp. 1-4
Author(s):  
Nasser Mikhail ◽  
Soma Wali
Keyword(s):  
Diabetes Mellitus ◽  
Animal Studies ◽  
Meta Analysis ◽  
Case Series ◽  
Glucocorticoid Therapy ◽  
Predisposing Factor ◽  
Patients With Diabetes ◽  
Pubmed Search ◽  
High Index Of Suspicion

Background: A surge of cases of Coronavirus Disease 2019 (COVID-19)-Associated Mucormycosis (CAM) was recently observed. Objective: To determine the contribution of diabetes and glucocorticoid therapy in predisposing to CAM. Methods: Pubmed search until July 2nd, 2021. Search terms included mucormycosis, diabetes, glucocorticoids, corticosteroids, coronavirus disease 2019, mortality. Randomized trials, case series, retrospective, pre-print studies, meta-analysis, professional guidelines are reviewed. Pertinent in vitro and animal studies are also included. Results: Diabetes mellitus was reported in 78-85% of cases of CAM worldwide, with the highest rates present in India. Diabetic Ketoacidosis (DKA) was observed in 3.5-41% of cases of CAM. Glucocorticoid therapy emerged as another predisposing factor occurring in 85% of cases of CAM. Injudicious use of glucocorticoids may be a contributing factor in a substantial proportion of subjects with CAM. Majority of patients develop symptoms of CAM between day 10 and 15 from the diagnosis of COVID-19. However, some cases of CAM may present up to 3 months after COVID-19 or following recovery from COVID-19. Mortality rates of CAM overall ranges from 34-48%. Surgical debridement may be associated with improved survival. Conclusions: High index of suspicion for CAM should be present in patients with diabetes and those receiving corticosteroids. Effective glycemic control and judicious use of glucocorticoids should be implemented to decrease incidence of CAM.

Abstract #856 A Case Series Review of Clinical and Biochemical Characteristics of Pituitary Abcess in Mexican Patients

2018 ◽  
Vol 24 ◽  
pp. 202-203
Author(s):  
Mireya Perez-Guzman ◽  
Alfredo Nava de la Vega ◽  
Arturo Pena Velarde ◽  
Tania Raisha Torres Victoria ◽  
Froylan Martinez-Sanchez ◽  
...  
Keyword(s):  
Case Series ◽  
Biochemical Characteristics ◽  
Mexican Patients

Cannabis-associated arteritis

VASA ◽  
2010 ◽  
Vol 39 (1) ◽  
pp. 43-53 ◽  
Author(s):  
Grotenhermen
Keyword(s):  
Systematic Review ◽  
Case Reports ◽  
Case Series ◽  
Cardiovascular Effects ◽  
Causative Factor ◽  
Cannabis Use ◽  
Thromboangiitis Obliterans ◽  
Pathological Features ◽  
Scientific Support ◽  
Clinical And Pathological Features

Background: To investigate the hypothesis that cases of arteritis similar to thromboangiitis obliterans (TAO) and associated with the use of cannabis were caused by cannabis or THC (dronabinol), or that cannabis use is a co-factor of TAO. Patients and methods: A systematic review on case reports and the literature on so-called cannabis arteritis, TAO, and cardiovascular effects of cannabinoids was conducted. Results: Fifteen reports with 57 cases of an arteritis associated with the use of cannabis and two additional case series of TAO, in which some patients also used cannabis, were identified. Clinical and pathological features of cannabis-associated arteritis do not differ from TAO and the major risk factor of TAO, tobacco use, was present in most, if not in all of these cases. The proposed pathophysiological mechanisms for the development of an arteritis by cannabis use are not substantiated. Conclusions: The hypothesis of cannabis being a causative factor or co-factor of TAO or an arteritis similar to TAO is not supported by the available evidence. The use of the term “cannabis arteritis” should be avoided until or unless more convincing scientific support is forthcoming.

Sign in / Sign up

Export Citation Format

Share Document